Your session is about to expire
← Back to Search
MEDI3506 for Diabetic Kidney Disease
Study Summary
This trial is testing a new drug to see if it can improve kidney function in people with diabetes.
- Diabetic Kidney Disease
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 148 Patients • NCT04212169Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many areas are executing the trial in this urban center?
"At present, 56 medical centres are enrolling patients in this trial. These locations include Atlanta, Wichita and Huntsville along with many others. To reduce the burden of travel, it is best to select a clinic nearest to you if considering participation."
What potential risks accompany the use of MEDI3506?
"MEDI3506's safety has been partially validated, so it was awarded a score of 2 on our scale. As this is only a Phase 2 trial, no efficacy data exists yet."
Are octogenarians included in this clinical investigation?
"For this clinical trial, participants must be aged 18-101. Separately, there are 45 trials available to minors and 503 studies open to elderly individuals."
Is this the pioneering endeavor of its type?
"MEDI3506 was first examined in 2014 by AstraZeneca, with a 700-person trial leading to its N/A drug approval. Nowadays, MEDI3506 is featured in 63 separate trials across 235 cities and 50 countries worldwide."
Have any other investigations taken place that involve MEDI3506?
"MEDI3506 was initially researched in 2014 at the University of Texas Health Science Center located in San Antonio. To date, 18453 clinical trials have been concluded with 63 currently active studies, a majority of which are being conducted out of Atlanta, Georgia."
Am I qualified to partake in this clinical trial?
"This medical experiment is searching for 609 individuals, aged 18 to 101, suffering from kidney diseases. The primary requirements are that they have type-2 diabetes, an estimated glomerular filtration rate between 25 and 75 mL/min/1.73 m2, a urinary albumin creatinine ratio of 100 to 3000 mg albumin/g creatinine, blood pressure lower than 150 over 100 mmHG, and a stable dose of ACE inhibitors or angiotensin receptor blockers (ARBs)."
What is the typical purpose of MEDI3506?
"MEDI3506 offers therapeutic solutions to address pharmaceuticals, dietary requirements and physical activity."
Is enrollment currently open for this clinical trial?
"According to clinicaltrials.gov, this trial is not presently recruiting patients and the most recently modified version of the posting was on October 20th 2022. In spite of this fact, there are 547 other medical studies that require human participants at present."
What is the participant capacity of this research endeavor?
"At present, this clinical trial is not recruiting. Initially posted on the 18th of November 2019 and most recently updated on October 20th 2022, it is currently inactive. However, there are presently 484 studies actively seeking patients with kidney diseases and 63 trials for MEDI3506 which are open to new participants."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger